Problems in the management of asthma in young children - A potential role for montelukast

South African Medical Journal

Volumn 94, Issue 9, 2004, Pages 746-748

  Green, Robin J ^a   Weinberg, Eugene G ^b  

^a Red Cross Children's Hospital ^*

^b RED CROSS WAR MEMORIAL CHILDREN S HOSPITAL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; ANTIINFLAMMATORY AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FENOTEROL PLUS IPRATROPIUM BROMIDE; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; MONTELUKAST; PREDNISOLONE; SALMETEROL XINAFOATE; ZAFIRLUKAST;

ABSENTEEISM; ASTHMA; CHILD; CHILDHOOD DISEASE; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; HUMAN; NOTE; PATIENT COMPLIANCE; PATIENT EDUCATION; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PREVALENCE; QUALITY OF LIFE; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ACETATES; ADOLESCENT; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; PATIENT COMPLIANCE; QUALITY OF LIFE; QUINOLINES; TREATMENT OUTCOME;

EID: 4644337098     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (15)

1. South African Childhood Asthma Working Group. Management of chronic childhood and adolescent asthma. S Afr Med J 1994; 84: 862-866.
2. Anderson HR, Bailey PA, Cooper JS, et al. Morbidity and school absence caused by asthma and wheezing illness. Arch Dis Child 1983; 58: 777-784.
3. Hill RA, Standen PJ, Tattersfield AE. Asthma, wheezing and school absence in primary schools. Arch Dis Child 1989; 64: 246-251.
4. Ninan TK, Russell G. Respiratory symptoms and atopy in Aberdeen school children: evidence from two surveys 25 years apart. BMJ 1992; 304: 873-875.
5. Ehrlich RI, du Toit D, Jordaan E, Volmink JA, Weinberg EG, Zwarenstein M. Prevalence and reliability of asthma symptoms in primary school children in Cape Town. Int J Epidemiol 1995; 24: 1138-1145.
6. International Study of Allergy and Asthma (ISAAC) Steering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis and atopic eczema. ISAAC. Lancet 1998; 351: 1225-1232.
7. Yunginger JW, Reed CE, O'Connell EJ, et al. A community-based study of the epidemiology of asthma. Incidence notes, 1964-1983. Am Rev Respir Dis 1992; 146: 888-894.
8. National Institute of Health. Guidelines for the Diagnosis and Management of Asthma. Expert Panel Report 2. NIH Publication No. 97-4051. Bethesda, Md: National Institute of Health, 1997.
9. Ferguson AC. Bronchial hyperresponsiveness in asthmatic children. Correlation with macrophages and eosinophils in bronchiolar lavage fluid. Chest 1989; 96: 988-992.
10. Centres for Disease Control and Prevention. Surveillance for asthma in United States, 1960-1995. Morb Mortal Wkly Rep 1998; 47: SS-1; 1-26
11. von Mutius E. The burden of childhood asthma. Arch Dis Child 2000; 82: suppl 2, 112-115
12. Sazonov Kocevar V, Jonsson L, Valovirta E, et al. Inpatient cost among pediatric patients with asthma in four Nordic Countries. European Congress of Allergy and Clinical Immunology, 9-13 May 2001, Berlin, Germany (abstract).
13. Cochrane MG, Bala MV, Downs KE, et al. Inhaled corticosteroids for asthma therapy: Patient compliance, devices and inhalation technique. Chest 2000; 117: 542-550.
14. Milgrom H, Bender B, Ackerson L, et al. Noncompliance and treatment failure in children with asthma. J Allergy Clin Immunol 1996; 98: 1051-1057.
15. Knorr B, Franchi LM, Bisgaard H, et al. Montelukast, a leukotriene receptor antagonist for the treatment of persistent asthma in children aged 2-5 years. Pediatrics 2001; 108: 1-10.